A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer.

Trial Profile

A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Ombrabulin (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms DISRUPT
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 29 Sep 2012 Primary endpoint "Progression-free-survival-duration" has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top